TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35035223
Drug: Meropenem treatment
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meropenem treatment
Study: 35035233
Drug: TAP-DEX group
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAP-DEX group (bupivacaine + 1 µg/kg dexmedetomidine)
Study: 35036077
Drug: Combined radiotherapy
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined radiotherapy and anti-PD-1 antibody camrelizumab
Study: 35036831
Drug: Ketamine as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine as an adjunctive therapy
Study: 35036831
Drug: Ketamine as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine as an adjunctive therapy for major depression
Study: 35037887
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care involving keeping written records of glucose values and contacting the diabetes team daily by telephone.
Study: 35037893
Drug: Optimized medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized medical treatment
Study: 35038983
Drug: Rimegepant 75
Normalized name: rimegepant 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimegepant 75 mg PRN
Study: 35039142
Drug: Ginger (Zingiberofficinale)
DrugBank: Ginger (DB10344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger (Zingiberofficinale) add-on therapy, 399 mg three times per day for 6 weeks
Study: 35039242
Drug: Nocturnal urine
Normalized name: Urin DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nocturnal urine production >90 ml/h (NUP90)
Study: 35039291
Drug: Camu Camu
Normalized name: CAMUSTINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camu Camu (CC) supplementation
Study: 35039952
Drug: Sulindac 150
Normalized name: sulindac 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulindac 150 mg twice daily
Study: 35040156
Drug: Adalimumab (s.c.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab (s.c. doses according to package insert)
Study: 35041493
Drug: Imatinib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib (400 mg once daily) plus binimetinib (30 mg twice daily)
Study: 35041751
Drug: Testosterone treatment
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone treatment (duration: 12 months)
Study: 35042068
Drug: Durvalumab 1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab 1500 mg every four weeks
Study: 35042460
Drug: Pelvic radiotherapy
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic radiotherapy treatment
Study: 35042555
Drug: Anti-CCP+ individuals
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-CCP+ individuals with high antibody levels
Study: 35042560
Drug: TXA 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: TXA 500 mg two times daily for 28 days
Study: 35042560
Drug: Placebo two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo two times daily for 28 days
Study: 35042560
Drug: TXA 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: TXA 500 mg
Study: 35043682
Drug: Subsequent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subsequent treatment for mCRC patients
Study: 35043682
Drug: Patient-reported outcomes
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-reported outcomes using a modified version of the ACCEPTance by the Patients of their Treatment
Study: 35043686
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of pembrolizumab and laser interstitial thermal therapy
Study: 35043976
Drug: VB124 (MCT4
Approvals — FDA: no, EMA: no, PMDA: no
Description: VB124 (MCT4 inhibitor)
Study: 35043976
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of MCT4 inhibition and anti-PD-1 immunotherapy
Study: 35045184
Drug: Hyperglycemia and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperglycemia and higher insulin doses
Study: 35045358
Drug: Intravenous CAR
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous CAR T cells administered intrapleurally (10-186 mL) via image-guided techniques (intracavitary or intratumoral)
Study: 35045358
Drug: Intravenous CAR
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous CAR T cells administered intrapleurally
Study: 35045815
Drug: Various palliative
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various palliative interventions for ESCC including chemotherapy, radiation therapy (with and without chemotherapy), and esophageal stenting with self-expandable metallic stents.
Study: 35045989
Drug: Remdesivir (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remdesivir (200 mg IV on day 0, followed by 100 mg IV daily for 10 days)
Study: 35046056
Drug: VIP152 monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VIP152 monotherapy (30 mg, once-weekly intravenous infusion)
Study: 35046132
Drug: Steroid-sparing immunosuppressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid-sparing immunosuppressive protocol
Study: 35046132
Drug: Control of
Normalized name: A replication-competent adenovirus type 5 in which the E1A and E1B genes are under the control of a human telomerase reverse transcriptase (hTERT) and IRES, respectively.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control of mineral metabolism
Study: 35046747
Drug: Mindfulness meditation
Normalized name: benzalkonium chloride Topical Foam [Meditize]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness meditation (five 30-minute weekly sessions)
Study: 35046880
Drug: Oral mannitol
Normalized name: Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral mannitol (18 g per day)
Study: 35047784
Drug: Pharmacological therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological therapy after revascularisation
Study: 35050753
Drug: Molecular-based recommended
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Molecular-based recommended therapy (MBRT)
Study: 35050753
Drug: Targeted therapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted therapies provided in the setting of a clinical trial or through compassionate use programs
Study: 35050961
Drug: Interdisciplinary multimodal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interdisciplinary multimodal pain therapy
Study: 35051703
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy (cCRT) with trametinib (1.5 mg)
Study: 35051950
Drug: Severe intraoperative
Normalized name: acetaminophen / diphenhydramine hydrochloride Oral Tablet [Tylenol Severe Allergy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Severe intraoperative hyperglycemia (SIH) with blood glucose concentration (BGC) ≥180 mg/dL
Study: 35051950
Drug: No severe
Approvals — FDA: no, EMA: no, PMDA: no
Description: No severe intraoperative hyperglycemia (BGC <180 mg/dL)
Study: 35051950
Drug: Intraoperative BGC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative BGC >140 mg/dL
Study: 35058275
Drug: Non-curative ESD
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-curative ESD followed by surgical treatment (n=126)
Study: 35058326
Drug: isatuximab (anti-CD38
Approvals — FDA: no, EMA: no, PMDA: no
Description: isatuximab (anti-CD38 monoclonal antibody) + cemiplimab (anti-PD-1 monoclonal antibody)
Study: 35059291
Drug: Nonsurgical traditional
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nonsurgical traditional Korean medical treatment
Study: 35060907
Drug: InTSHA intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: InTSHA intervention (mobile phone-based intervention using WhatsApp, 10 modules conducted weekly)
Study: 35060914
Drug: Microbial Ecosystem
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Microbial Ecosystem Therapeutic-2 (MET-2), 3 capsules per day for 8 weeks
Study: 35061769
Drug: Hypertension (defined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertension (defined as known hypertension or use of antihypertensive medication)
Study: 35062926
Drug: Fruit and
Normalized name: elderberry fruit and flower 460 mg-115 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fruit and Vegetable Prescription Program (FVPP) with high exposure (> 24 months)
Study: 35062926
Drug: Fruit and
Normalized name: elderberry fruit and flower 460 mg-115 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fruit and Vegetable Prescription Program (FVPP) with moderate exposure (12-24 months)
Study: 35062926
Drug: Fruit and
Normalized name: elderberry fruit and flower 460 mg-115 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fruit and Vegetable Prescription Program (FVPP) with no previous exposure
Study: 35062987
Drug: Intravenous vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous vitamin C supplementation (40 mg/kg)
Study: 35063276
Drug: Olaparib maintenance
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib maintenance monotherapy (300 mg twice daily)
Study: 35064011
Drug: Dostarlimab 500
Normalized name: Dostarlimab
DrugBank: Dostarlimab (DB15627)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dostarlimab 500 mg every 3 weeks for 4 cycles, then 1000 mg every 6 weeks until disease progression (cohort A1, dMMR/MSI-H)
Study: 35064011
Drug: Dostarlimab 500
Normalized name: Dostarlimab
DrugBank: Dostarlimab (DB15627)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dostarlimab 500 mg every 3 weeks for 4 cycles, then 1000 mg every 6 weeks until disease progression (cohort A2, MMRp/MSS)
Study: 35065058
Drug: Neoadjuvant cemiplimab
Normalized name: cemiplimab
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Neoadjuvant cemiplimab 350 mg intravenously every 3 weeks for 2 cycles followed by surgical resection.
Study: 35065599
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose of 0.2 mg/kg of cisatracurium
Study: 35065785
Drug: arsa-cel (gene
Approvals — FDA: no, EMA: no, PMDA: no
Description: arsa-cel (gene therapy)
Study: 35066531
Drug: Dual-source photon-counting
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-source photon-counting detector computed tomography (PCD-CT) with late enhancement (LE) scan using 100 mL contrast media.
Study: 35066693
Drug: Crenolanib 100
Normalized name: Crenolanib
DrugBank: Crenolanib (DB11832)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crenolanib 100 mg BID with paclitaxel 80 mg/m² and ramucirumab
Study: 35067072
Drug: Intracoronary CD34+
Normalized name: Autologous CD34+ cells encoding βA-T87Q-Globin gene
DrugBank: Betibeglogene autotemcel (DB16900)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary CD34+ cell therapy
Study: 35067230
Drug: Vigabatrin (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vigabatrin (single loading dose of 4500 mg via enteric tube within 48 h of PASE onset)
Study: 35067596
Drug: Phone-delivered mindfulness
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phone-delivered mindfulness training (MT) for 30 minutes weekly for 8 weeks
Study: 35067748
Drug: Change in
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Change in antibiotic treatment
Study: 35067817
Drug: Non-ablative Er:YAG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-ablative Er:YAG laser treatment (IncontiLase® procedure)
Study: 35067817
Drug: Single-session maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-session maintenance treatments every 6 months
Study: 35067817
Drug: Non-ablative Er:YAG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-ablative Er:YAG laser treatment
Study: 35067914
Drug: Steroid treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid treatment, specific dosage and duration not available
Study: 35068788
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of autologous HSC and MSC infusion
Study: 35068788
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (G-CSF) administration
Study: 35070795
Drug: PDE-5 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PDE-5 inhibitors
Study: 35070991
Drug: Citarinostat 360
Normalized name: Citarinostat
DrugBank: Citarinostat (DB15449)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citarinostat 360 mg once daily plus paclitaxel 80 mg/m²
Study: 35070991
Drug: Citarinostat 480
Normalized name: Citarinostat
DrugBank: Citarinostat (DB15449)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citarinostat 480 mg once daily plus paclitaxel 80 mg/m²
Study: 35070991
Drug: Citarinostat 180
Normalized name: Citarinostat
DrugBank: Citarinostat (DB15449)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citarinostat 180 mg once daily plus paclitaxel 80 mg/m²
Study: 35071653
Drug: Low-dose group
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose group (24 patients)
Study: 35071653
Drug: Medium-dose group
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dose group (25 patients)
Study: 35071653
Drug: High-dose group
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose group (24 patients)
Study: 35072135
Drug: Chronic RASI
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic RASI therapy
Study: 35072135
Drug: In-hospital RASI
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-hospital RASI therapy
Study: 35072168
Drug: Ustekinumab 90
Normalized name: ustekinumab 90 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ustekinumab 90 mg maintenance weeks 0/4/16/28/40
Study: 35073853
Drug: COVID-19 antigen
Normalized name: COVID-19 antigen vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: COVID-19 antigen and antibody associations
Study: 35073963
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal medicine (CHM) prescribed based on pattern differentiation in addition to conventional medication (ConM)
Study: 35073963
Drug: Conventional medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional medication (ConM) only
Study: 35074020
Drug: Low-calorie diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-calorie diet (840 kcal/day) for weight loss and diabetes remission, 12-week duration, monitored weekly for weight and blood glucose.
Study: 35074072
Drug: Ibrutinib-rituximab induction
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ibrutinib-rituximab induction (12 cycles; oral ibrutinib 560 mg daily and intravenous rituximab 375 mg/m2)
Study: 35074072
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment approach (ibrutinib-rituximab followed by R-HCVAD)
Study: 35075450
Drug: mRNA BNT162b2
Normalized name: SARS-CoV-2 vaccine, mRNA BNT162b2 bivalent original & OMICRON (BA.4/.5) 0.3 ML Injection, 12y+ (EUA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA BNT162b2 vaccine (two doses)
Study: 35076282
Drug: AZD7442 (300-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD7442 (300-mg intramuscular injection)
Study: 35076282
Drug: AZD7442 (prophylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD7442 (prophylactic administration)
Study: 35076282
Drug: AZD7442 (therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD7442 (therapeutic administration)
Study: 35076703
Drug: Vamorolone (≥2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vamorolone (≥2.0 mg/kg/d)
Study: 35076931
Drug: Ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 4 mg intravenous dose
Study: 35078538
Drug: Transcutaneous auricular
Normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous auricular vagus nerve stimulation (taVNS) for five minutes daily for 26 weeks.
Study: 35078739
Drug: Selinexor 60mg
Normalized name: SELINEXOR 60MG WEEKLY PKT
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Selinexor 60mg twice weekly
Study: 35079044
Drug: Fluid challenge
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid challenge with 250 mL crystalloids
Study: 35079784
Drug: INO-4800 (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: INO-4800 (0.5 mg, 1.0 mg, and 2.0 mg)
Study: 35079784
Drug: INO-4800 (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: INO-4800 (2.0 mg)
Study: 35080076
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for sinonasal malignancies
Study: 35081106
Drug: Psychological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychological treatment for school attendance problems (SAPs)
Study: 35081293
Drug: mRNA-1273 (Moderna)
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1273 (Moderna) at a dose of 100 μg
Study: 35081293
Drug: Ad26.COV2.S (Johnson
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad26.COV2.S (Johnson & Johnson-Janssen) at a dose of 5×10^10 viral particles
Study: 35081550
Drug: Herbal/dietary supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal/dietary supplements (HDS)
Study: 35081732
Drug: Inactive SARS-CoV-2
Normalized name: SARS-CoV-2 Sclamp
DrugBank: SARS-CoV-2 Sclamp (DB15849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive SARS-CoV-2 vaccination (inactivated virus vaccine)
Study: 35082572
Drug: LAR subtype
Normalized name: Influenza A virus subtype H3N2 haemagglutinin, recombinant
DrugBank: Influenza A virus subtype H3N2 haemagglutinin, recombinant (DB16642)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAR subtype after standard adjuvant or neoadjuvant chemotherapy
Study: 35082572
Drug: Non-LAR disease
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-LAR disease after standard adjuvant or neoadjuvant chemotherapy
Study: 35083234
Drug: Intracameral conbercept
Normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intracameral conbercept injection
Study: 35083365
Drug: Inactivated quadrivalent
Normalized name: influenza virus vaccine, inactivated quadrivalent intramuscular suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated quadrivalent influenza vaccine
Study: 35084435
Drug: BQ-788 (selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: BQ-788 (selective ETB antagonist)
Study: 35084584
Drug: Dental implants
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dental implants placed in patients on HDAR (bisphosphonates and denosumab)
Study: 35084584
Drug: Abutment operation
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Abutment operation performed 4 months after implant placement
Study: 35085462
Drug: Tocilizumab (TCZ)
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab (TCZ) administered to 15 patients
Study: 35086123
Drug: Intra-articular injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injections of LPC16:0
Study: 35086148
Drug: Aromatase Inhibitors
Normalized name: Aromatase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase Inhibitors (AIs)
Study: 35086481
Drug: Direct antiviral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct antiviral agents
Study: 35086504
Drug: Customized adherence
Normalized name: sulfur
DrugBank: Octasulfur (DB09353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Customized adherence enhancement intervention combined with long-acting injectable antipsychotic medication (LAI)
Study: 35086504
Drug: Long-acting injectable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting injectable antipsychotic medication (LAI)
Study: 35086949
Drug: Curative-intent dose-dense
Normalized name: CUR-1916
DrugBank: CUR-1916 (DB17838)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curative-intent dose-dense anthracycline and cyclophosphamide (ddAC)
Study: 35087084
Drug: Early booster
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early booster Vi-DT vaccine
Study: 35087084
Drug: Late booster
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late booster Vi-DT vaccine
Study: 35087595
Drug: Heat-clearing Traditional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat-clearing Traditional Chinese Medicine (TCM) individualized decoction
Study: 35087595
Drug: Control (individualized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (individualized decoction without heat-clearing drugs)
Study: 35088348
Drug: Nemolizumab (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nemolizumab (60 mg loading dose at baseline, followed by 30 mg every 4 weeks until week 12) with background topical corticosteroids or calcineurin inhibitors.
Study: 35088348
Drug: Nemolizumab treatment.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nemolizumab treatment.
Study: 35088735
Drug: Intraoperative neuromonitoring
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative neuromonitoring with evoked compound action potentials (ECAP) and late response (LR) recording
Study: 35089449
Drug: Digital Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital Pill System (DPS) for measuring PrEP adherence
Study: 35090035
Drug: Intravenous contrast
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous contrast agent administration
Study: 35090035
Drug: Intra-arterial contrast
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial contrast agent administration